How Long Has Mounjaro Been Around, and What Does That Mean for You?

The misconception: Mounjaro is a new, untested medicine

A question our prescribers hear most weeks is some version of: "Is Mounjaro safe, hasn't it only just come out?" It is a fair instinct. The UK licence for weight management is relatively recent, and novelty and risk can feel like the same thing. They are not.

Tirzepatide (the molecule branded as Mounjaro) was synthesised and entered early-phase human trials in the early 2010s. Phase 3 of the SURPASS diabetes programme, which ran across tens of thousands of patient-years and led to US FDA approval for type 2 diabetes in May 2022, generated a body of safety and efficacy data before the weight-management trials even finished recruiting. By the time the MHRA reviewed the SURMOUNT programme ahead of the UK weight-management licence, the cumulative evidence base was substantial. "New to your pharmacy shelf" and "new to science" are entirely different things, and in this case they are years apart.

The NHS medicines page for tirzepatide reflects the post-approval synthesis of that evidence, covering both the mechanism and the known side-effect profile built up across the full clinical programme.

The actual timeline: from molecule to NICE recommendation

The key dates are worth setting out plainly. Early-phase research on tirzepatide's dual GIP and GLP-1 receptor agonism was underway by the mid-2010s. Phase 3 diabetes trials (the SURPASS series) began around 2019. The US FDA approved tirzepatide for type 2 diabetes in May 2022 under the brand name Mounjaro. In parallel, the SURMOUNT weight-management programme recruited; SURMOUNT-1 results were published in the New England Journal of Medicine in 2022, reporting around 20–21% average weight loss at 72 weeks on the 15mg dose among adults with obesity but without diabetes. The MHRA granted the UK weight-management licence in November 2023. NICE then completed its own independent appraisal, recommending tirzepatide in TA1026 published on 23 December 2024.

That sequence matters because each step involves independent scrutiny of the same underlying data. The NICE recommendation, in particular, only comes after the committee has examined the full clinical evidence, modelled cost-effectiveness and reviewed the safety signal. You can read more about how long tirzepatide has been used in clinical settings internationally for additional context on the pre-UK evidence base.

For those curious about the earlier research stages, how long Mounjaro has been tested covers the trial programme in more detail.

What the evidence actually showed, and why the timeline is relevant to results

The length of the trials is directly relevant to the results figures that appear in coverage of this medicine. SURMOUNT-1 ran for 72 weeks, not the shorter durations typical of early obesity trials. That matters because weight loss with tirzepatide is not a sharp early event; it continues to accumulate over many months as doses are titrated and the body adapts. Quoting a 12-week figure misrepresents what the 72-week data showed.

At the highest dose studied, around 20–21% average body-weight reduction was observed. The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, found that tirzepatide produced greater average weight loss than semaglutide 2.4mg over a comparable period, which informed the NICE committee's assessment. Those figures describe populations in controlled trials; individual results vary, and a prescriber assesses your specific picture. If you want to understand how quickly the effect tends to emerge in practice, how long Mounjaro takes to work covers the expected progression week by week.

It is also worth knowing that Mounjaro carries a Black Triangle (▼) designation from the MHRA, meaning it is subject to additional safety monitoring. That is standard for medicines approved within the past five years and does not indicate an unresolved safety concern, it means new reports are actively collected and reviewed. See how long Mounjaro has been on the market for a fuller discussion of the post-approval monitoring picture.

Where to go from here

Understanding the history is useful; it tells you the evidence was built carefully and reviewed by multiple independent bodies. What it cannot do is confirm whether tirzepatide is appropriate for you. Eligibility depends on BMI, weight-related conditions and a full medical history, factors a prescriber weighs individually. If you are considering treatment, the practical next step is a consultation with a GPhC-registered clinician who can apply the evidence to your situation.

You can explore the full Mounjaro treatment overview to understand what the process involves, or look at the weight-loss treatment options at nume if you want to compare routes before deciding anything. For a clear-eyed look at what treatment costs in the private market, Mounjaro prices explained sets out the honest context. And if you have already started treatment and have concerns about consistency of response, Mounjaro not working the second time around addresses that specific question.

When you are ready, check your eligibility through a free consultation with our prescribers.